Aspire Biopharma Holdings (ASBP) Cash & Current Investments (2022 - 2026)

Aspire Biopharma Holdings (ASBP) has reported Cash & Current Investments for 5 consecutive years, with $12.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Current Investments rose 4766.85% year-over-year to $12.2 million in Q2 2026; TTM through Jun 2026 was $12.2 million, a 4766.85% increase from a year earlier, with the FY2025 full-year figure at $1.0 million, up 27532.92% from the prior year.
• Cash & Current Investments was $12.2 million for Q2 2026 at Aspire Biopharma Holdings, up from $5.9 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $12.2 million in Q2 2026 and troughed at $3633.0 in Q4 2024.
• A 5-year average of $1.4 million and a median of $406205.5 in 2022 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments sank 97.75% in 2023 and soared 27532.92% in 2025, its largest moves.
• Over 5 years, Cash & Current Investments stood at $497259.0 in 2022, then slumped by 97.75% to $11174.0 in 2023, then tumbled by 67.49% to $3633.0 in 2024, then soared by 27532.92% to $1.0 million in 2025, then soared by 1111.98% to $12.2 million in 2026.
• The last three Cash & Current Investments figures came in at $12.2 million (Q2 2026), $5.9 million (Q1 2026), and $1.0 million (Q4 2025), per Business Quant data.